
A study examined the efficacy and safety of adalimumab in pediatric patients (< 18 years old) with chronic non-infectious posterior uveitis and panuveitis. Among 69 children analyzed, those receiving adalimumab (ADA group) showed superior improvement in ocular parameters compared to those in the conventional adalimumab-free treatment group (CT group). The ADA group achieved earlier alleviation of symptoms and higher remission rates within 3 months, with fewer relapses during follow-up. Adalimumab effectively treated pediatric uveitis, improved visual outcomes, and maintained disease stability with manageable adverse effects.
Like
Save
Share